- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00032175
Gemcitabine With or Without Capecitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
A Phase III Multicenter Randomized Clinical Trial Comparing Gemcitabine Alone Or In Combination With Capecitabine For The Treatment Of Patients With Advanced Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if gemcitabine is more effective with or without capecitabine in treating pancreatic cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of gemcitabine with or without capecitabine in treating patients who have locally advanced or metastatic pancreatic cancer.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
OBJECTIVES:
- Compare the 1-year survival rate of patients with locally advanced or metastatic pancreatic cancer treated with gemcitabine with or without capecitabine.
- Compare the median and 2-year survival rates and the objective response rates of patients treated with these regimens.
- Compare the toxicity of these regimens in these patients.
- Compare the quality of life of patients treated with these regimens.
OUTLINE: This is an randomized, open-label, multicenter study. Patients are stratified according to disease stage (locally advanced vs metastatic) and performance status (0 and 1 vs 2). Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15 and oral capecitabine twice daily on days 1-21. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
- Arm II: Patients receive gemcitabine IV over 30 minutes on days 1, 8, 15, 22, 29, 36, and 43 during the first course. After a 1-week rest period, patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15. Subsequent courses repeat every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.
Quality of life is assessed at baseline, every 3 months for 1 year, and then annually thereafter.
Patients are followed every 3 months.
Peer Reviewed and Funded or Endorsed by Cancer Research UK
PROJECTED ACCRUAL: A total of 508 patients (254 per treatment arm) will be accrued for this study.
Tipo de estudio
Inscripción (Anticipado)
Fase
- Fase 3
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
England
-
Bath, England, Reino Unido, BA1 3NG
- Royal United Hospital
-
Bournemouth, England, Reino Unido, BH7 7DW
- Royal Bournemouth Hospital
-
Bristol, England, Reino Unido, BS2 8ED
- Bristol Haematology and Oncology centre
-
Cambridge, England, Reino Unido, CB2 2QQ
- Addenbrooke's Hospital at Cambridge University Hospitals NHS Foundation Trust
-
Derby, England, Reino Unido, DE1 2QY
- Derbyshire Royal Infirmary
-
Exeter, England, Reino Unido, EX2 5DW
- Royal Devon and Exeter Hospital
-
Ipswich, England, Reino Unido, IP4 5PD
- Ipswich Hospital NHS Trust
-
King's Lynn, England, Reino Unido, PE30 4ET
- Queen Elizabeth Hospital
-
Leeds, England, Reino Unido, LS16 6QB
- Cookridge Hospital at Leeds Teaching Hospital NHS Trust
-
Leicester, England, Reino Unido, LE1 5WW
- Leicester Royal Infirmary
-
Lincoln, England, Reino Unido, LN2 5QY
- Lincoln County Hospital
-
Liverpool, England, Reino Unido, L69 3GA
- Royal Liverpool University Hospital
-
Liverpool, England, Reino Unido, L3 9TA
- Cancer Research UK Liverpool Cancer Trials Unit
-
London, England, Reino Unido, SE1 7EH
- St. Thomas' Hospital
-
Manchester, England, Reino Unido, M20 4BX
- Christie Hospital NHS Trust
-
Merseyside, England, Reino Unido, CH63 4JY
- Clatterbridge Centre for Oncology NHS Trust
-
Middlesbrough, Cleveland, England, Reino Unido, TS4 3BW
- James Cook University Hospital at South Tees Hospitals NHS Trust
-
Newcastle-Upon-Tyne, England, Reino Unido, NE4 6BE
- Northern Centre for Cancer Treatment at Newcastle General Hospital
-
Norwich, England, Reino Unido, NR4 7UY
- Norfolk and Norwich University Hospital
-
Plymouth, England, Reino Unido, PL6 8DH
- Derriford Hospital
-
Poole Dorset, England, Reino Unido, BH15 2JB
- Poole Hospital NHS Trust
-
Prescot Merseyside, England, Reino Unido, L35 5DR
- Whiston Hospital
-
Preston, England, Reino Unido, PR2 9HT
- Royal Preston Hospital
-
Salisbury, England, Reino Unido, SP2 8BJ
- Salisbury District Hospital
-
Southampton, England, Reino Unido, SO14 0YG
- Royal South Hants Hospital
-
Stoke-On-Trent, England, Reino Unido, ST4 7LN
- University Hospital of North Staffordshire
-
Sutton, England, Reino Unido, SM2 5PT
- Royal Marsden NHS Foundation Trust - Surrey
-
Warrington, England, Reino Unido, WA5 1QG
- Warrington Hospital NHS Trust
-
-
Scotland
-
Aberdeen, Scotland, Reino Unido, AB25 2ZN
- Aberdeen Royal Infirmary
-
-
Wales
-
Swansea, Wales, Reino Unido, SA2 8QA
- Singleton Hospital of the Swansea NHS Trust
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
DISEASE CHARACTERISTICS:
Histologically or cytologically confirmed ductal adenocarcinoma of the pancreas
- Locally advanced or metastatic disease not amenable to curative surgical resection
- Macroscopic residual disease after prior resection with histological confirmation is allowed
- Unidimensionally measurable disease
- No intracerebral metastases or meningeal carcinomatosis
PATIENT CHARACTERISTICS:
Age:
- Over 18
Performance status:
- WHO 0-2
Life expectancy:
- More than 3 months
Hematopoietic:
- WBC greater than 3,000/mm3
- Neutrophil count greater than 1,500/mm3
- Platelet count greater than 100,000/mm3
Hepatic:
- Bilirubin less than 2 mg/dL
Renal:
- Creatinine less than 2 mg/dL
- Creatinine clearance greater than 50 mL/min
Cardiovascular:
- No New York Heart Association class III or IV heart disease
- No uncontrolled angina pectoris
Other:
- No other prior malignancy except nonmelanoma skin cancer or carcinoma in situ of the cervix
- No other concurrent uncontrolled medical condition
- No other medical or psychiatric condition that would preclude study
- No known hypersensitivity to fluorouracil
- No dihydropyrimidine dehydrogenase deficiency
- No known malabsorption syndromes
- Not pregnant or nursing
- Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- Not specified
Chemotherapy:
- No prior chemotherapy (including preoperative or adjuvant) for this disease
- No other concurrent cytotoxic chemotherapy
Endocrine therapy:
- Not specified
Radiotherapy:
- No prior radiotherapy (including preoperative or adjuvant) for this disease
Surgery:
- See Disease Characteristics
Other:
- No prior investigational drugs (including preoperative or adjuvant) for this disease
- No other concurrent investigational drugs
- No concurrent dipyridamole or allopurinol
- No concurrent sorivudine or sorivudine analogs (e.g., brivudine) (capecitabine arm only)
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Enmascaramiento: Ninguno (etiqueta abierta)
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
---|
Supervivencia a 1 año
|
Medidas de resultado secundarias
Medida de resultado |
---|
Toxicidad
|
Calidad de vida
|
Tasa de respuesta objetiva
|
Median survival rate
|
Survival rate at 2 years
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Emily Owen, Cancer Research UK
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades del Sistema Digestivo
- Neoplasias
- Neoplasias por sitio
- Enfermedades del sistema endocrino
- Neoplasias del Sistema Digestivo
- Neoplasias de glándulas endocrinas
- Enfermedades pancreáticas
- Neoplasias pancreáticas
- Efectos fisiológicos de las drogas
- Mecanismos moleculares de acción farmacológica
- Agentes antiinfecciosos
- Agentes Antivirales
- Inhibidores de enzimas
- Antimetabolitos, Antineoplásicos
- Antimetabolitos
- Agentes antineoplásicos
- Agentes inmunosupresores
- Factores inmunológicos
- Gemcitabina
- Capecitabina
Otros números de identificación del estudio
- CRUK-GEM-CAP
- CDR0000069263 (Identificador de registro: PDQ (Physician Data Query))
- EU-20116
- ISRCTN11513444
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Cancer de pancreas
-
Abramson Cancer Center of the University of PennsylvaniaTerminadoPaciente con cancerEstados Unidos
-
Peking Union Medical College HospitalTerminadoEncuesta | Estado nutricional | Paciente con cancerPorcelana
-
Ankara Medipol UniversityReclutamientoCuidados personales | Inmunoterapia | Manejo de síntomas | Paciente con cancerPavo
-
Northwestern UniversityGenzyme, a Sanofi CompanyRetiradoCANCER DE PROSTATAEstados Unidos
-
Fundacao ChampalimaudTerminado
-
University College London HospitalsTerminado
-
GenSpera, Inc.RetiradoCancer de prostata.Estados Unidos
-
University of Colorado, DenverColorado State UniversityRetiradoRealidad virtual | Diagnóstico por imagen | Educación del paciente | Paciente con cancerEstados Unidos
-
Dana-Farber Cancer InstituteTerminadoCancer de RIÑON | Cancer de prostata | Cáncer genitourinarioEstados Unidos
-
Rabin Medical CenterReclutamiento